On Aug. 26, 2020, Heat Biologics announced publication of positive preclinical COVID-19 results in bioRxiv. The company reported that bioRxiv elicited a robust immune response directed against the Spike protein of SARS-CoV-2, generating both helper CD4+ T-cells that aide in antibody production, as well as virus killing cytotoxic CD8+ T cells